ArticleQuantitative imaging in medicine and surgery2025
Comparison of bone ingrowth and clinical outcome of a collagen-hydroxyapatite bone graft substitute versus autologous bone graft in posterior lumbar interbody fusion.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posterior lumbar interbody fusion (PLIF) is a surgical procedure to treat painful unstable spinal segments using bone graft filled interbody cages and instrumentation. The graft can be autologous bone or a bone substitute. RegenOss is a porous, 3-dimensional composite bone substitute consisting of collagen fibers including hydroxyapatite. The aim of this cohort study was to evaluate RegenOss as graft material in PLIF patients, as compared to a historical cohort grafted with autologous bone. Methods: Fifteen patients were enrolled prospectively at the Maastricht University Medical Center between November 2016 and May 2019 in the RegenOss cohort (METC14-1-056) and were compared to 15 matched prospective patients from a historical autologous cohort collected at the Maastricht University Medical Center between October 2011 and January 2014 (METC10-1-025). During PLIF, interbody cages were filled with RegenOss bone substitute in the RegenOss cohort and with local autologous bone in the autologous cohort. Both cohorts were subjected to patient reported outcome measures (PROMs) [including Oswestry Disability Index (ODI), Visual Analogue Scale (VAS), EuroQol-5D (EQ-5D)], 18F-fluoride positron emission tomography/computed tomography (PET/CT) at six weeks and one year. Interbody fusion was assessed on CT at one year and bone metabolism on 18F-fluoride PET/CT was assessed at six weeks and one year. Differences in patient demographics, clinical outcome, interbody fusion and bone metabolism were assessed between graft cohorts. Bone metabolism was also compared between follow-up moments. Results: Patient demographics were comparable between cohorts. At one-year follow-up, clinical outcome in both cohorts was similar (ODI: P=0.12, VAS: P=0.15, EQ-5D: P=0.22). Interbody fusion was considered comparable between cohorts; 7/15 RegenOss patients and 8/15 autologous patients were scored as completely fused on CT at one year. Similar findings in bone metabolism between follow-up moments were found for both cohorts; bone metabolism in the operated segment was significantly lower at one year compared to at six weeks (RegenOss cohort: P=0.003, P=0.005 for the upper and lower endplate respectively, autologous cohort: P=0.001, P=0.001). No differences in bone metabolism were observed between cohorts. Conclusions: Bony bridging, clinical outcome, bone metabolism were comparable for the RegenOss and the autologous bone graft PLIF cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.